Comparative effectiveness and safety of factor-xa inhibitors vs phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study

Authors:
H Bonnemeier¹, R Kreutz², D Enders³, N Schmedt³, D Haeckl⁴, T Vaitsiakhovich⁵, S Kloss⁵, ¹University Medical Center of Schleswig-Holstein - Kiel - Germany, ²Charite - Campus Mitte (CCM), Institute of Clinical Pharmacology and Toxicology - Berlin - Germany, ³Ingef - Institute for Applied Health Research Berlin - Berlin - Germany, ⁴WIG2 - Scientific Institute for Health Economics and Health Service Research - Leipzig - Germany, ⁵Bayer AG, Real World Evidence and Outcomes Data Generation - Berlin - Germany,

Topic(s):
Oral Anticoagulation

Funding Acknowledgements:
The study was funded by Bayer AG

Background
Data on safety and effectiveness of Factor-Xa inhibitors and phenprocoumon in patients with non-valvular atrial fibrillation (NVAF) and malignant diseases is scarce. Among others, our study aimed to investigate the safety and effectiveness in new users of Factor-Xa inhibitors vs. phenprocoumon, the vitamin-K antagonist (VKA) of choice in Germany.

Methods
We conducted a new user cohort study (one year washout period) in patients with NVAF and malignant diseases. German claims data between January 1st, 2013 and June 30th, 2017 were utilized and a multiple Cox-regression was performed to calculate confounder-adjusted hazard ratios (HRs) for the risk of ischemic stroke (IS)/systemic embolism (SE), intracranial haemorrhage (ICH) as well as renal function worsening, defined by end stage renal disease (ESRD) or dialysis and acute kidney injury (AKI) in Factor-Xa inhibitors and phenprocoumon initiators. Diagnoses of malignant diseases were assessed over the one-year baseline period.

Results
The population comprised 3,779 phenprocoumon initiators, 3,386 rivaroxaban initiators, 2,697 apixaban initiators and 434 edoxaban initiators. In the confounder-adjusted analysis, no difference related to the risk of IS/SE was found for rivaroxaban and edoxaban vs. phenprocoumon, where apixaban showed a numerically increased risk for stroke (figure 1). Point estimates related to the risk of ICH showed the expected beneficial effects for both, rivaroxaban and apixaban. A strong beneficial effect was observed for rivaroxaban when assessing the risk of renal function worsening. Hazard ratios related to the risk of ESRD/dialysis and AKI were 0.27 (0.10; 0.69) and 0.64 (0.38; 1.06), respectively. For apixaban, only the ESRD/dialysis showed a reduction in risk when compared to phenprocoumon, HR 0.42 (0.19; 0.94).

Conclusion
This retrospective database study conducted in Germany adds evidence on the effectiveness and safety profile of Factor-Xa inhibitors over VKA in patients with NVAF and malignant diseases, a critical subgroup of patients where anticoagulation is challenging. However, apixaban showed a numerically increased risk for IS/SE compared to phenprocoumon. Both, rivaroxaban and apixaban showed a risk reduction for renal function worsening within the study period of 63% and 48%, respectively compared to phenprocoumon. Only rivaroxaban showed a risk reduction of 36% for AKI.
Abstract: P4781
Comparative effectiveness and safety of factor-Xa inhibitors vs. phenprocoumon in patients with non-valvular atrial fibrillation and malignant diseases, insights from the RELOADED study

Authors: H Bonnemeier 1, R Kreutz 2, D Enders 3, N Schmedt 3, D Haeckl 4, T Vaitsiakhovich 5, S Kloss 5
1 University Medical Center of Schleswig-Holstein – Kiel – Germany, 2 Charite – Campus Mitte (CCM), Institute of Clinical Pharmacology and Toxicology – Berlin – Germany, 3 Ingef – Institute for Applied Health Research Paris – France, 4 WIG2 – Scientific Institute for Health Economics and Health Service Research – Leipzig – Germany, 5 Bayer AG, Real World Evidence and Outcomes Data Generation – Berlin – Germany

Topic(s): Oral Anticoagulation

Citation:

Background
Data on safety and effectiveness of Factor-Xa inhibitors and phenprocoumon in patients with non-valvular atrial fibrillation (NVAF) and malignant diseases is scarce. Among others, our study aimed to investigate the safety and effectiveness in new users of Factor-Xa inhibitors vs. phenprocoumon, the vitamin-K antagonist (VKA) of choice in Germany.

Methods
We conducted a new user cohort study (one year washout period) in patients with NVAF and malignant diseases. German claims data between January 1st, 2013 and June 30th, 2017 were utilized and a multiple Cox-regression was performed to calculate confounder-adjusted hazard ratios (HRs) for the risk of ischemic stroke (IS)/systemic embolism (SE), intracranial haemorrhage (ICH) as well as renal function worsening, defined by end stage renal disease (ESRD) or dialysis and acute kidney injury (AKI) in Factor-Xa initiators. Diagnoses of malignant diseases were assessed over the one-year baseline period.

Results
The population comprised 3,779 phenprocoumon initiators, 3,386 rivaroxaban initiators, 2,697 apixaban initiators and 434 edoxaban initiators. In the confounder-adjusted analysis, no difference related to the risk of IS/SE was found for rivaroxaban and edoxaban vs. phenprocoumon, where apixaban showed a numerically increased risk for stroke (figure 1). Point estimates related to the risk of ICH showed the expected beneficial effects for both, rivaroxaban and apixaban. A strong beneficial effect was observed for rivaroxaban when assessing the risk of renal function worsening. Hazard ratios related to the risk of ESRD/dialysis and AKI were 0.27 (0.10; 0.69) and 0.64 (0.38; 1.06), respectively. For apixaban, only the ESRD/dialysis showed a reduction in risk when compared to phenprocoumon, HR 0.42 (0.19; 0.94).

Conclusion
This retrospective database study conducted in Germany adds evidence on the effectiveness and safety profile of Factor-Xa inhibitors over VKA in patients with NVAF and malignant diseases, a critical subgroup of patients where anticoagulation is challenging. However, apixaban showed a numerically increased risk for IS/SE compared to phenprocoumon. Both, rivaroxaban and apixaban showed a risk reduction for renal function worsening within the study period of 63% and 48%, respectively compared to phenprocoumon. Only rivaroxaban showed a risk reduction of 36% for AKI.